| 279.59 1.15 (0.41%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 338.21 | 1-year : | 366.06 |
| Resists | First : | 289.56 | Second : | 313.41 |
| Pivot price | 277.07  |
|||
| Supports | First : | 251 | Second : | 208.83 |
| MAs | MA(5) : | 274.31 |
MA(20) : | 282.97 |
| MA(100) : | 306.53 |
MA(250) : | 275.91 |
|
| MACD | MACD : | -7.9 |
Signal : | -8.8 |
| %K %D | K(14,3) : | 49.4 |
D(3) : | 41.9 |
| RSI | RSI(14): 44.9 |
|||
| 52-week | High : | 343.11 | Low : | 211.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BIO ] has closed below upper band by 44.9%. Bollinger Bands are 25% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 282.49 - 283.32 | 283.32 - 284.26 |
| Low: | 271.04 - 272.05 | 272.05 - 273.19 |
| Close: | 277.78 - 279.33 | 279.33 - 281.06 |
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Mon, 02 Mar 2026
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a 16.36% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Sun, 01 Mar 2026
Artisan Partners Limited Partnership Has $24.22 Million Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Fri, 27 Feb 2026
Is It Time To Reconsider Bio-Rad Laboratories (BIO) After Its Prolonged Share Price Slump - simplywall.st
Fri, 27 Feb 2026
Westfield Capital Management Co. LP Increases Stock Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Thu, 26 Feb 2026
Bio-Rad Laboratories, Inc. $BIO Shares Sold by Vanguard Group Inc. - MarketBeat
Thu, 19 Feb 2026
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 22 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 16.3 (%) |
| Held by Institutions | 90.6 (%) |
| Shares Short | 819 (K) |
| Shares Short P.Month | 864 (K) |
| EPS | 27.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 276.16 |
| Profit Margin | 29.4 % |
| Operating Margin | 8.8 % |
| Return on Assets (ttm) | 1.6 % |
| Return on Equity (ttm) | 10.8 % |
| Qtrly Rev. Growth | 3.9 % |
| Gross Profit (p.s.) | 61.13 |
| Sales Per Share | 117.7 |
| EBITDA (p.s.) | 19.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 532 (M) |
| Levered Free Cash Flow | 256 (M) |
| PE Ratio | 10.03 |
| PEG Ratio | 0 |
| Price to Book value | 1.01 |
| Price to Sales | 2.37 |
| Price to Cash Flow | 11.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|